Mechanism · Research Data · Side Effects · No Doses
Mazdutide is a Chinese-developed peptide that hits two receptors at once, GLP-1 and glucagon, aiming to combine appetite suppression with extra calorie burn. It has been through a real Phase 3 programme in China for obesity and type 2 diabetes and is already approved there. It is not approved in Ireland or the EU, and almost all the trial data so far comes from Chinese populations, so how well it generalises elsewhere is not yet established.
| Evidence Type | Status |
|---|---|
| Human RCT | ✔ |
| Observational | ✗ |
| Animal Studies | ✔ |
| In Vitro | ✔ |
| Regulatory Approval | Approved in China for weight management indications following Phase 3 data; not approved in EU/Ireland as of most recent published data |
Phase 3 trials conducted by Innovent Biologics in Chinese populations with obesity reported significant weight loss with mazdutide across studied doses over 24-48 week trial periods, with higher-dose arms reporting weight loss broadly comparable in magnitude to other advanced incretin-based therapies studied in similar trial designs.
Mazdutide has also been studied in people with type 2 diabetes, where trials reported reductions in HbA1c alongside weight loss and improvements in some lipid parameters, consistent with the combined GLP-1/glucagon mechanism under investigation.
Given the glucagon receptor's role in hepatic lipid metabolism, a specific area of research interest for mazdutide (shared with other GLP-1/glucagon dual agonists) is its potential effect on liver fat content, with some trial sub-analyses reporting reductions in markers associated with hepatic steatosis alongside the primary weight and glycaemic endpoints.
| Study / Model | Reported Effect |
|---|---|
| Phase 2 Obesity Trial (China, Innovent Biologics) | Reported dose-dependent weight loss versus placebo over 24 weeks, supporting progression to Phase 3. |
| Phase 3 Obesity Trial (China, published trial data) | Reported meaningful percentage body weight reduction at higher studied doses over 48 weeks versus placebo, comparable in direction and magnitude to other dual-agonist incretin therapies in the class. |
| Phase 3 Type 2 Diabetes Trial (China) | Reported HbA1c reduction and weight loss in participants with type 2 diabetes over the trial period, with a tolerability profile broadly consistent with the GLP-1/glucagon dual-agonist class. |
| Preclinical Rodent Dual-Receptor Studies | Confirmed combined GLP-1/glucagon receptor engagement translating to reduced food intake and increased energy expenditure markers in animal models, supporting the translational rationale for human trials. |
This site does not publish doses, durations or frequencies for any compound. Published research protocols for this compound vary considerably between studies in design, intensity and duration. Those details are not something to copy from a fitness website — anyone researching this compound should read the primary literature directly and talk to a doctor who knows their bloods.
Reported tolerability profile across trials was broadly consistent with the known adverse event pattern of GLP-1/glucagon dual-agonist agents as a class; gastrointestinal effects were the most frequently reported reason for dose adjustment or discontinuation in published trial data.
Research base note: Mazdutide's clinical trial programme has been conducted predominantly in Chinese trial populations, with results disclosed via peer-reviewed publication and major diabetes/obesity conference presentations (ADA, EASD) as the Phase 3 programme has matured. Independent, large-scale trial data in European or Irish populations is not yet published as of the most recent available data, and the compound is not approved for use in Ireland or the EU. Readers should treat cross-population efficacy and safety extrapolation with appropriate caution.
What is Mazdutide?
Mazdutide is a dual GLP-1/glucagon receptor agonist developed by Innovent Biologics, designed to combine GLP-1-driven appetite suppression with glucagon receptor activity linked to increased energy expenditure and hepatic fat metabolism.
Is Mazdutide approved for use in Ireland?
No. Mazdutide is approved in China for weight management indications following its Phase 3 programme there, but it is not approved in the EU or Ireland as of the most recently published data, and independent European or Irish trial data does not yet exist.
How is Mazdutide different from Semaglutide (Ozempic/Wegovy)?
Semaglutide acts on the GLP-1 receptor alone. Mazdutide adds glucagon receptor activation on top of that, a mechanism researchers believe may add increased energy expenditure and effects on liver fat to the appetite-suppression effect GLP-1 alone provides, though this is a Chinese trial finding and not a head-to-head comparison against Western trial data.
What side effects has Mazdutide research reported?
Gastrointestinal effects, including nausea, vomiting and diarrhoea, were the most common, consistent with the wider GLP-1/glucagon dual-agonist class, alongside increased heart rate reported in some studies linked to glucagon receptor activity.
Reconstitution calculator, dosing-frequency planner and cycle-length calculator. No signup required.
Open the Peptide CalculatorsTracking food too? Free calorie counter with barcode scanner →